Austedo access in the United Arab Emirates: the EDE named-patient pathway

Last reviewed 2026-05-12 by the Reserve Meds clinical and regulatory team. This page combines the UAE country research module with the Austedo drug module to describe the path families actually walk.

Quick orientation

Austedo (deutetrabenazine) is a deuterated small-molecule vesicular monoamine transporter 2 (VMAT2) inhibitor developed by Teva Pharmaceuticals. The US Food and Drug Administration approved Austedo in April 2017 for chorea associated with Huntington's disease, and in August 2017 for tardive dyskinesia in adults. A once-daily extended-release formulation marketed as Austedo XR was approved in February 2023. Typical maintenance doses range from 12 mg to 48 mg daily, titrated to clinical response and tolerability. The deuteration extends the molecule's half-life and supports a more stable plasma profile than the parent compound tetrabenazine. Reserved for you.

Why UAE patients need Austedo via a named-patient pathway

Tardive dyskinesia presents in the UAE adult psychiatric population at the rate consistent with long-duration antipsychotic exposure, and Huntington's disease appears at the expected rare-disease prevalence. The locally available VMAT2-inhibitor option historically has been tetrabenazine, which carries a higher peak-trough variability and a higher rate of depressive and parkinsonian adverse events. Austedo's deuteration profile is the clinical case for the next-step option when tetrabenazine has not been tolerated or has not delivered adequate control. Valbenazine (Ingrezza) is the other US-approved VMAT2 inhibitor and is positioned similarly. The two drugs are not interchangeable; the treating neurologist or psychiatrist selects between them based on patient response and the dosing pattern.

Austedo is not consistently held in UAE federal stock at the level a chronic neurology medication would warrant. The EDE named-patient pathway is the established route when the treating neurologist or psychiatrist has documented the clinical case for deutetrabenazine specifically.

The EDE / MoHAP named-patient pathway applied to Austedo

The federal pathway for a UAE-licensed physician to obtain a medicine that is not registered or not stocked locally is the unregistered-medicine import permit, administered through the Emirates Drug Establishment (EDE) at ede.gov.ae. The EDE took over 44 core services from MoHAP under Federal Decree-Law No. 38 of 2024 on 29 December 2025. The framework allows hospitals and licensed pharmaceutical establishments to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority such as the US FDA and a locally registered alternative is not suitable.

For Austedo, the clinical justification packet is straightforward but carries the standard psychiatric medication safeguards. The treating neurologist or psychiatrist documents the diagnosis (Huntington's chorea or tardive dyskinesia), severity (chorea scale or AIMS for tardive dyskinesia), prior therapy trail (antipsychotic exposure history with timing for tardive dyskinesia cases, tetrabenazine trial outcome where applicable, anticholinergic and beta-blocker trials where relevant), depression history given the VMAT2 class boxed warning, and the rationale for deutetrabenazine over the alternatives. The letter typically references the Teva US label.

A complete EDE application for Austedo typically includes the specialist's clinical justification letter, the treating physician's MoHAP, DHA, DoH, or Sharjah Health Authority licence verification, an anonymised patient identifier, full product details (Austedo 6 mg, 9 mg, or 12 mg tablets, or Austedo XR once-daily tablets), the destination dispensing pharmacy name with licence number and pharmacy in charge, and the patient informed consent including the boxed-warning discussion on depression and suicidality. Approval timelines for routine cases are 5 to 15 business days. Complex submissions extend to 4 to 6 weeks.

Where Austedo gets dispensed in the UAE

Austedo is an oral tablet with standard ambient storage at 20 to 25 degrees Celsius. The dispensing site is the outpatient pharmacy attached to the prescribing neurology or psychiatry clinic. The most natural dispensing sites are neurology and psychiatry services at Cleveland Clinic Abu Dhabi, Sheikh Khalifa Medical City, American Hospital Dubai, Mediclinic City Hospital, NMC Royal Hospital in Khalifa City, and the psychiatry departments at Al Amal Psychiatric Hospital in Dubai and the Behavioural Sciences Pavilion at Sheikh Khalifa Medical City. Reserve Meds does not select the dispensing pharmacy on the patient's behalf. We coordinate the documentation and the logistics; the treating physician and the patient pick the dispensing site.

Real cost picture for Austedo in the UAE

The US wholesale acquisition cost for Austedo is approximately USD 9,000 to 12,000 per month at typical maintenance doses (24 mg to 48 mg daily), translating to approximately AED 33,000 to 44,000 monthly at the 3.67 peg. The figure is the drug acquisition cost only.

All-in delivered cost stacks the drug acquisition, international logistics (USD 400 to 800 per shipment, ambient temperature), EDE handling and customs (USD 300 to 600 per case), the dispensing pharmacy fee, and the Reserve Meds concierge coordination fee. We quote each case after the documentation review so the patient sees a firm range before any wire. Insurance in the UAE handles VMAT2 inhibitor cases case by case. Pre-authorisation is the norm. Thiqa, Daman, GIG Gulf, Sukoon, ADNIC, and Orient each assess individually. We supply the documentation set; we do not promise coverage.

Typical timeline for Austedo in the UAE

The EDE permit processes in 5 to 15 business days for a routine submission with a clear clinical role. International logistics adds 3 to 7 business days for an ambient-shipped oral medication. Customs clearance is typically 1 to 3 business days. A patient who completes the documentation in week one typically receives the first prescription in week three to week five. Titration to maintenance dose follows the Teva US label and is managed by the treating specialist; the supply cadence is monthly thereafter.

What your physician needs to provide

The clinical justification letter for an Austedo EDE submission is short and clinically precise. The treating neurologist or psychiatrist's letter typically addresses the diagnosis (Huntington's chorea or tardive dyskinesia), the severity quantification (UHDRS Total Motor Score or chorea sub-score for HD, AIMS for tardive dyskinesia), the prior therapy trail (antipsychotic history for TD, tetrabenazine outcome where trialled, behavioural and dietary considerations), the depression and suicidality history given the boxed warning, and the rationale for deutetrabenazine. The letter references the Teva US label and the proposed titration schedule.

The patient signs informed consent that explicitly references the boxed warning on depression and suicidality. The treating physician's licence must be in active standing in the emirate of the dispensing facility (MoHAP for the Northern Emirates, DHA for Dubai, DoH for Abu Dhabi and Al Ain, Sharjah Health Authority for Sharjah).

Pharmacovigilance considerations

Austedo carries a boxed warning for depression and suicidality in Huntington's disease patients. The treating specialist documents baseline mood at initiation and structures monthly check-ins for the first three months and quarterly thereafter. The VMAT2 class also carries a risk of parkinsonism, akathisia, and neuroleptic malignant syndrome. Pharmacovigilance follow-up is standard. Adverse events identified by the treating team route to Teva's safety reporting channel and to the EDE post-market surveillance address. CYP2D6 status influences metabolism; the US label includes dose adjustment guidance for poor metabolisers and patients taking strong CYP2D6 inhibitors.

Common questions about Austedo in the UAE

Why Austedo and not tetrabenazine or valbenazine? The three molecules sit in the same VMAT2 inhibitor class but differ in dosing pattern, half-life, and adverse-event profile. Tetrabenazine has the longer history and is more widely available regionally but requires multiple daily doses and a higher rate of depressive and parkinsonian adverse events. Valbenazine (Ingrezza) is once-daily but covers only tardive dyskinesia in its US label, not Huntington's chorea. Austedo is deuterated for a steadier plasma profile and covers both indications. The clinical choice rests with the treating specialist.

Will Daman, Thiqa, or my private insurer cover this? Each insurer assesses VMAT2 inhibitor cases case by case. Pre-authorisation is the norm. Thiqa has the broadest specialty coverage. We do not promise coverage.

Is Austedo a controlled substance? No. Austedo is not a DEA scheduled substance. It is a prescription medication with a boxed warning, which is a different regulatory category from controlled substance scheduling.

Can I switch directly from tetrabenazine to Austedo? The US label provides a tetrabenazine-to-Austedo conversion table. The treating specialist supervises the switch.

What patients and families ask when they first call

"How does the case actually start?" The patient, family, or treating specialist contacts Reserve Meds through the waitlist form. Within 24 to 48 hours, a coordinator confirms eligibility, sends the documentation kit to the physician, and outlines the EDE submission sequence. No payment is taken at this stage. The firm quote follows once the documentation is reviewed and the EDE pathway is confirmed.

"How is the boxed-warning conversation handled?" The treating neurologist or psychiatrist documents the depression and suicidality baseline at initiation and structures the monitoring schedule (monthly for the first three months, quarterly thereafter). For Huntington's disease patients, this is part of the standard chronic-care plan because the underlying neurodegenerative disease independently carries depression risk. The conversation is led by the treating clinician, not by Reserve Meds.

"What happens during dose titration?" The Teva US label specifies a starting dose of 6 mg twice daily, titrated weekly in 6 mg/day increments to clinical response and tolerability. Most patients reach maintenance between 12 mg and 48 mg daily. For Austedo XR, the equivalent once-daily titration follows the conversion table. The treating clinician supervises titration.

"What if I'm taking a strong CYP2D6 inhibitor or am a poor metaboliser?" The US label provides specific maximum-dose guidance for CYP2D6 poor metabolisers and for patients on strong CYP2D6 inhibitors such as fluoxetine, paroxetine, or bupropion. The treating clinician adjusts accordingly. CYP2D6 phenotyping is not universally required but is increasingly available regionally.

Where Reserve Meds fits in Austedo cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating neurologist or psychiatrist, the EDE, or the dispensing pharmacy. For an Austedo case, our work is the regulatory documentation assembly, the US-side procurement coordination with Teva's specialty distributor, the logistics, the customs handoff, and a single named coordinator for the patient through onboarding and the recurring monthly supply. Reserved for you.

Documentation kit for the treating specialist

The documentation kit Reserve Meds sends the treating neurologist or psychiatrist after a waitlist confirmation contains the EDE clinical-justification letter template tailored to the VMAT2 inhibitor class, the chorea or AIMS scoring template, the prior antipsychotic and prior VMAT2 inhibitor capture sheet, the depression and suicidality baseline-and-monitoring template referencing the boxed warning, the titration schedule template covering the standard regimen and the CYP2D6 dose adjustment options, the patient informed consent template, the dispensing pharmacy intake checklist, and the post-initiation adverse-event capture sheet. The kit is built so the treating clinic spends minimum time on form work and maximum time on the clinical conversation that anchors the EDE submission and the boxed-warning monitoring schedule.

Next step

If a treating neurologist or psychiatrist in the UAE is weighing Austedo for an adult patient, the waitlist is the first step. We respond within 24 to 48 hours with an eligibility confirmation and a documentation kit for the physician.

Join the Austedo waitlist

Reserved for you.

Related

• Austedo clinical resource
• Huntington's disease
• Tardive dyskinesia
• United Arab Emirates country page

Sources

1. FDA approval, Austedo (deutetrabenazine), Teva Pharmaceuticals, approval April 2017 for Huntington's chorea and August 2017 for tardive dyskinesia; Austedo XR approval February 2023.
2. UAE Federal Decree-Law No. 38 of 2024 and the Emirates Drug Establishment portal at ede.gov.ae.
3. Teva Pharmaceuticals US prescribing information for Austedo and Austedo XR, including boxed warning on depression and suicidality.